Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Oral administration at a dose of 2.5 mg once daily for a 4-week cycle

Oral administration at a dose of 1 mg once daily for a 4-week cycle

Oral administration at a dose of 25 mg once daily with a meal every 4 weeks

Fulvestrant: IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle

IV infusion, every 2 weeks, 4 weeks per treatment cycle